The DOI matches its Crossref record.
Adverse events and efficacy of TNF- blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients
Abstract
OBJECTIVE: To follow-up on all available infliximab-treated SLE patients for safety and long-term efficacy in order to extract information that is useful for planning appropriate controlled trials with infliximab in SLE. METHODS: We analysed charts of six patients treated in an open-label safety trial and seven additional patients treated with infliximab on a compassionate care basis for uncontrolled SLE organ inflammation. RESULTS: Out of nine patients with lupus nephritis, six had a long-term response after four infusions of infliximab in combination with AZA, lasting for up to 5 years. All five patients with lupus arthritis responded, but this response did not last for >2 months after the last infusion. One additional patient had a long-lasting improvement in SLE interstitial lung disease. No symptoms suggestive of infliximab-induced SLE flares occurred in any patients. Short-term treatment appeared relatively safe, but one patient developed deep-vein thrombosis and several infections. Under long-term therapy, two patients had life-threatening or fatal events, namely CNS lymphoma and Legionella pneumonia. Retreatment and treatment without concomitant immunosuppression led to drug reactions. CONCLUSIONS: Short-term therapy with four infusions of infliximab in combination with AZA was relatively safe, and had remarkable long-term efficacy for lupus nephritis and, potentially, also interstitial lung disease. Long-term therapy with infliximab, however, was associated with severe adverse events in two out of three SLE patients, which may have been provoked by infliximab and/or by their long-standing refractory SLE and previous therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Kaul, A., Gordon, C., Crow, M. K., Touma, Z., Urowitz, M. B., van Vollenhoven, R., Ruiz-Irastorza, G., & Hughes, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.39 · Cited by 1,391
Self-citationMurine Models of Systemic Lupus Erythematosus
Perry, D., Sang, A., Yin, Y., Zheng, Y.-Y., & Morel, L. (2011) · BioMed Research International · doi:10.1155/2011/271694 · Cited by 378
Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets
Guan, F., Wang, R., Yi, Z., Luo, P., Liu, W., Xie, Y., Liu, Z., Xia, Z., Zhang, H., & Cheng, Q. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02124-y · Cited by 371
The Role of Monocytes and Macrophages in Autoimmune Diseases: A Comprehensive Review
Ma, W.-T., Gao, F., Gu, K., & Chen, D.-K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01140 · Cited by 361
Metadata
- Authors
- Aringer, M., Houssiau, F., Gordon, C., Graninger, W. B., Voll, R. E., Rath, E., Steiner, G., & Smolen, J. S.
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-09-11
- Volume
- 48
- Issue
- 11
- Pages
- 1451-1454
- ISSN
- 1462-0324 (ISSN-L)
- 1462-0332
- OpenAlex
- W2103258308
- Cited by
- 194
- References
- 0
- FWCI
- 13.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adverse events and efficacy of TNF- blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. https://app.cochat.ai/papers/10.1093/rheumatology/kep270
- The paper
- Aringer, M., Houssiau, F., Gordon, C., Graninger, W. B., Voll, R. E., Rath, E., Steiner, G., & Smolen, J. S. (2009). Adverse events and efficacy of TNF- blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology. https://doi.org/10.1093/rheumatology/kep270
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.